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with good long term results even in a peripheral center.
Left main coronary patients usually present in hemodynamically
compromised state warranting immediate intervention not giving
enough time to shift to well-equipped center in metro cities. This study
should bolster the conﬁdence of those working in periphery to under-
take leftmain interventions especially in rescue situations to save lives.CELL THERAPY AND ANGIOGENESIS (TCTAP A-145)
TCTAP A-145
Globular Adiponetin Protects Mesenchymal Stem Cells Against Hypoxia
and Serum Deprivation Induced Apoptosis via the AdipoR1/AMPK Pathway
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BACKGROUND Bone marrow-derived mesenchymal stem cells (MSCs)
transplantation is a promising therapy for cardiac repair. However, poor
viability of transplanted MSCs within the ischemic heart has limited their
therapeutic potential. Hypoxia and serum deprivation (H/SD) was widely
used to mimic the ischemic myocardium microenvironment and induced
MSCs apoptosis through the mitochondrial apoptotic pathway. Adipo-
nectin (APN) is an adipocyte-secreted adipokine with pleiotropic actions.
Accumulating evidence suggests that the physiological roles of APN go
beyond its metabolic effects and participate in tissue regeneration and
promote the survival of several other stem cells. We embarked on investi-
gating the role of APN in the prevention of MSCs against H/SD-induced
apoptosis and elucidated the potential mechanisms involved.
METHODS Rat bone marrow MSCs were exposed to H/SD with
different concentrations (0, 0.01, 0.1, 1 ug/ml) of globular APN in a
sealed GENbox hypoxic chamber for 12 hours. MSCs were transfected
with adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2) siRNAs to
determine the major receptor type that mediated the actions of APN.
For pathway studies, the cells were pre-incubated with AMPK inhib-
itor Compound C. Apoptosis was detected by Annexin V staining and
measuring caspase-3 activity. Mitochondrial dysfunction was
analyzed by measuring expression of Bcl-2 and Bax.
RESULTS H/SD-induced apoptosis was attenuated by globular APN in
a concentration-dependent manner evidenced by reduced Annexin V
stained positive cells and decreased caspase-3 activity. This protective
effect of APN was mainly mediated through AdipoR1. Moreover, APN
increased the phosphorylation of AMPK and Compound C effectively
reversed the anti-apoptotic effect of APN. Furthermore, APN signiﬁ-
cantly increased the expression of Bcl-2 and decreased Bax expres-
sion. The inhibition of the AdipoR1 or AMPK pathway partly abolished
the effect of APN on mitochondrial dysfunction.
CONCLUSION These data demonstrated that globular APN prevents
H/SD - induced apoptosis and mitochondrial dysfunction in MSCs via
AdipoR1 linked to the activation of downstream AMPK pathway. Our
ﬁndings indicate that APN is a novel, potent survival factor for MSCs
in the ischemic myocardium.COMPLEX (TCTAP A-146 TO TCTAP A-147)
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BACKGROUND In recent years, major technical advances in intra-
aortic balloon pumping (IABP) catheters have beenmade, including the
introduction of low-proﬁle catheters and the use of percutaneous
insertion through a sheath introducer. To date, many clinical studies
have conﬁrmed the impact of lower proﬁle IABP catheters on the inci-
dence of vascular complications. Recently, the 6-Fr IABP catheter was
introduced for clinical use in Japan, and its feasibility and efﬁcacy have
already been reported; it is expected to further reduce the incidence of
access site complications, For the insertion of 6-Fr IABP catheters,
usually the dedicated 6-Fr sheath introducer is used; however, with the
recent development of sheath introducers, the use of the 6-Fr sheath
introducer, which has a thinner wall structure and the same outer
diameter compared to the conventional 5-Fr introducer, has been
established for percutaneous coronary intervention (PCI). This intro-
ducer is currently distributed for trans-radial access only, as it may kink
in the absence of a guiding catheter or inner sheath if used for the
brachial or femoral approach owing to its very thin size. However, wehypothesize that this introducer can be safely used for the 6-Fr IABP, as
the caliber of the puncture site becomes virtually 5-Fr, and that thismay
contribute to further reduction of access site complications, thus
allowing early ambulation of patients undergoing coronary interven-
tion. Accordingly, in this study, we evaluated the feasibility of hemo-
dynamic support with 6-Fr IABP catheters during PCI, using this sheath
introducerwith thinwall structure. To the best of our knowledge, this is
theﬁrst feasibility study for application of theGlide sheath Slenderwith
the 6-Fr IABP catheter.
METHODS Between May 2014 and October 2014, 13 patients with
acute coronary syndrome underwent percutaneous coronary inter-
vention (PCI) using a 6-Fr IABP catheter through a6-Fr Glide sheath
Slender for support. The adverse events, including access site com-
plications, kinking of the sheath during the procedure, and any evi-
dence of balloon pump failure, were retrospectively investigated.
RESULTS Baseline characteristics of the patients and insertion procedure.
A total of 13 patients were evaluated. The mean age of the patients
was 70.1years and all patients were men. The mean height and body
weight were 164.2 cm and 66.1 kg, respectively. The insertion and
subsequent balloon pumping were successful in all cases. The IABP
catheter was inserted through the femoral artery in 12 (92.3%) patients
and through the left brachial artery in 1 (7.7%) patient for whom the
femoral approach was contraindicated (Fig. 1-5). The mean support
time was 26.4  16.3 h. Kinking of the introducer shaft occurred during
the insertion procedure in one patient; however, the subsequent
balloon pumping was well maintained and did not require exchange of
the sheath or IABP catheter. In another case, strong resistance was
observed during IABP catheter insertion in the sheath, probably owing
to incomplete vacuum suction during preparation of the IABP catheter.
Complications
No patient experiencedmajor access site bleeding; however, 1 patient
who underwent trans brachial insertion experienced minor bleeding in
the approach site. No patient developed severe limb ischemia. Helium
leakage or poor helium inﬂation necessitating catheter exchange did
not occur in any case. One patient, who was undergoing extracorporeal
membrane oxygenation, experienced cardiopulmonary arrest outside
the hospital and subsequently died of multi-organ failure. However, no
death related to the IABP catheter insertion was observed.
CONCLUSION Although it has several limitations, the use of the 6-Fr
IABP catheter through a 6-Fr slender sheath resolved issues related to
approach site limitations and access site-related complications.
Further investigations are required to conﬁrm our ﬁndings.
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BACKGROUND Ostial left anterior descending coronary artery (LAD)
lesion is an important target for coronary revascularization because its
location subtends a large territory of myocardium. An ostial stenosisis
an angiographic narrowing of  70% located within 3 mm of the vessel
origin. Ostial lesions have a reputation of being ﬁbrotic, calciﬁed, and
relatively rigid. Ostial disease is felt to be additionally resistant to
dilatation and prone to recoil due to the greater thickness of muscular
and elastic tissue in the aortic wall. Greater degrees of rigidity and
recoil resulted in lower acute gain and higher rates of TLR. In addi-
tion, procedural complications such as dissections, vessel closure and
myocardial infarction were more frequent. Strategies for LAD Ostial
PCI are Proximal strut of stent extended into distal LM, Stenting
Covering the Distal LMCA, Precise Location at Ostium.
Sometime Stent placement may be difﬁcult due to excessive stent
movement Aim of the study was to evaluate a simple an innovative
technique to deal with signiﬁcant LAD ostial lesion. (Fig 1- LAD ostial
stenosis)
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2010 and February 2013. 48 consecutive patients with signiﬁcant
angiographic ostial LAD (oLAD) lesion and 160 non ostial LAD (non-
oLAD) lesion were included. PCI of LAD ostial lesions pose unique
challenges. Decision must be taken whether precise positioning of the
stent at the ostium should be attempted or stenting across the LCX
back into the LM is preferable (Fig 2).
Our strategies were precise location of stent implantation at ostium
(Fig 3 & 4). Simultaneous balloon placement from distal LM to prox-
imal LCX may prevent the unwanted stent movement during its
placement and also properly guides us for precise stent placement at
the LAD ostium.
In this study baseline clinical characteristics were obtained. Clinical
success was deﬁned as angiographic success plus the absence of major
adverse cardiac events (MACE). MACE was also recorded on follow up.RESULTS Patients with oLAD versus non-oLAD PCI were almost
similar age (589 vs.567) and more frequently male (83% vs.69%,
p¼0.03). oLAD were mostly smoker (28% vs. 16% p¼0.02) and had
higher prevalence of diabetes (20% vs. 11%, p¼0.04), more often
presented with NSTEMI (44% vs. 24%, p¼0.008). Mostly they have
history of previous myocardial infarction (24% vs. 13%, p¼0.02) and
admission ejection fraction (EF) <50% were signiﬁcantly more in
oLAD group (12% vs. 9%, p¼0.04).
The o LAD group had higher incidence of multi vessel disease (30%
vs. 18, p¼0.02) and more likely to be calciﬁed (26% vs. 18%, p¼0.001).
Procedural success (TIMI III) were high in both groups (94% vs. 96%,
p¼0.7). The oLAD had higher incidence of post PCI LVF (5.2%
vs.1.25%, p¼0.02).
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p¼0.11), subsequent CABG (2.1% vs. 2.5%, p¼0.59) and all-cause mor-
tality (0.5% vs. 1.25%, p¼0.51) were statistically similar in both groups.
CONCLUSION Precise stent placement may be difﬁcult in complex
LAD ostium lesion due to unwanted movement & angulation.
Simultaneous balloon placement is technically simple approach for
prevention of unwanted stent movement.
Keeping balloon in LM to LCX during LAD ostial stent placement is
very much helpful & can be applied in clinical practice. Operator
should also consider 7 Fr guiding catheter, Superzooming, RAO caudal
or LAO caudal view, DES stent with high radial force.
Our technique is quick, effective and technically simple for precise
stent placement at LAD ostium. Present data also support this unique,
innovative & simple technique. Further large scale studies into the
optimal LAD ostial stenting are warranted to establish this technique.DRUG-ELUTING STENTS (TCTAP A-148 TO TCTAP A-152)
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BACKGROUND Although drug-eluting stents (DES) markedly reduced
the incidence of in-stent restenosis (ISR), the risk of the stent
thrombosis (ST) cannot be ignored. In previous studies, comparison of
predictors of ST between bare metal stent and DES were studied
mainly. The aim of this study was to evaluate the differences of pre-
dictors of ST between 1stgeneration and 2nd generation DES after
percutaneous coronary intervention (PCI).
METHODS 2117 patients who underwent PPCI due to acute myocardial
infarction were enrolled since January 2006 to December 2013. The
1stgeneration drug-eluting stent (DES) included the Cypher and Taxus.
The 2ndgeneration DES included Resolute, Xience and Promus.
RESULTS ST was shown in 39 patients (1.84%). 1st generation DES
was used in 30 patients (30/1084 ¼ 2.8%) and 2nd generation DES was
used in 9 patients (9/1033 ¼ 0.9%). Patients who used 1st generation
DES showed signiﬁcantly higher ST rate compared with patients who
used 2nd generation DES (p 0.001). In patients treated with 1st gen-
eration DES, younger age (RR 0.956, CI 0.926-0.987, p¼0.006) and
hypertension (2.494, 1.136-5.478, 0.023) were associated with the
increased risk of stent thrombosis. In patients treated with 2nd gen-
eration DES, younger age (0.888, 0.828-0.952, 0.001), lower ejection
fraction (0.904, 0.842-0.970, 0.005), multi stent (5.676, 1.255-25.671,
0.024) were associated with the increased risk of ST.
CONCLUSION Patients who treated with 1st generation DES showed
higher incidence rate of ST compared with 2nd generation DES. Although
there were similar independent predictors of ST for both DES such as
younger age, there were also different predictors as hypertension for 1st
generation DES and lower ejection fraction for 2nd generation DES.TCTAP A-149
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BACKGROUND Clinical outcome of the intervention for isolated left
circumﬂex (LCx) ostial lesion is uncertain. The aim of this study is to
investigate the outcomes of ﬁrst and second generation drug-eluting
stent (DES) implantation for isolated LCx ostial disease.
METHODS This is a single center, retrospective study. Between April
2007 and March 2013, a total of 10755 percutaneous coronary in-
terventions (PCI) were performed in our hospital. Among these, we
performed elective DES implantation for 77 stable patients with iso-
lated LCx ostial lesions. 19 Sirolimus-eluting stents and 15 Paclitaxel-
eluting stents were implanted. (34 patients in ﬁrst generation group)
10 Zotarolimus-eluting stents, 25 Everolimus-eluting stents and 8
Biolimus A9-eluting stents were implanted. (43 patients in second
generation group) We evaluated their backgrounds and clinical out-
comes. The end points were the occurrence of major adverse cardiac
events (MACE) and target lesion revascularization (TLR).
RESULTS First and second generation groups were followed up for
1359669 days and 900454 days. Backgrounds are similar in
2groups. Kaplan-Meier survival curves showed that freedom from
MACE and TLR at 2years were 82.4% and 86.7% in second generation
group, compared with 78.4% and 84.3% in ﬁrst generation group.
(p¼0.53 and p¼0.43).
CONCLUSION Second generation DES offers no statistically signiﬁ-
cant advantage over ﬁrst generation DES in middle-term outcome of
PCI for isolated LCx ostial stenosis.
